共 50 条
- [41] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 47 - 58Adjei, Alex A.LoRusso, PatriciaRibas, AntoniSosman, Jeffrey A.Pavlick, AnnaDy, Grace K.Zhou, XiaofeiGangolli, EshaKneissl, MichelleFaucette, StephanieNeuwirth, RachelBozon, Viviana
- [42] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsCANCER DISCOVERY, 2017, 7 (07) : 704 - 715Juric, DejanKrop, IanRamanathan, Ramesh K.Wilson, Timothy R.Ware, Joseph A.Bohorquez, Sandra M. SanabriaSavage, Heidi M.Sampath, DeepakSalphati, LaurentLin, Ray S.Jin, HuanParmar, HemaHsu, Jerry Y.Von Hoff, Daniel D.Baselga, Jose
- [43] A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Goel, SanjayUlahannan, Susanna VarkeyOlszanski, Anthony J.LoRusso, PatriciaSanborn, Rachel E.Sharma, SunilEmens, Leisha A.Reilley, MatthewPriego, VictorLi, ShuliWang, BingxiaDong, LixianSachsenmeier, KrisGibbs, JohnGharavi, RobertMartinez, AlonzoProscurshim, IgorFram, Robert J.Gomez-Pinillos, AlejandroRasco, Drew W.
- [44] Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumorsEJC SUPPLEMENTS, 2009, 7 (02): : 133 - 133Kaneda, H.Okamoto, I.Satoh, T.Arao, T.Nishio, K.Sarashina, A.Konishi, K.Stopfer, P.Kaiser, R.Nakagawa, K.
- [45] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumorsInvestigational New Drugs, 2017, 35 : 47 - 58Alex A. AdjeiPatricia LoRussoAntoni RibasJeffrey A. SosmanAnna PavlickGrace K. DyXiaofei ZhouEsha GangolliMichelle KneisslStephanie FaucetteRachel NeuwirthViviana Bózon
- [46] A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185Flynn, M.Shapiro, G.LoRusso, P.Kristeleit, R.Patel, M.Infante, J.Giordano, H.Borrow, J.Jaw-Tsai, S.Burris, H., III
- [47] Phase 1 Dose-escalation Study of PF-04449913, an Oral Hedgehog Inhibitor in Patients with Select Solid TumorsEUROPEAN JOURNAL OF CANCER, 2012, 48 : 180 - 180Wagner, A.Messersmith, W.Shaik, N.Zheng, X.McLachlan, K.Cesari, R.Courtney, R.Levin, W.El-Khoueiry, A.
- [48] Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single-agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595)JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Campone, MarioPlummer, RuthStephens, PeterBrakchi, ZahirAissat-Daudigny, LouizaKasiborski, FabriceCambois, AnneMoachon, GilbertBrown, Peter D.Kayitalire, Louis
- [49] Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumorsCANCER RESEARCH, 2020, 80 (16)Bendell, Johanna C.Bedard, PhilippeBang, Yung-JueLoRusso, PatriciaHodi, StephenGordon, MichaelD'Angelo, SandraDesai, JayeshGarralda, ElenaItaliano, AntoineMyung-Ju AhnCervantes, AndresWainberg, ZevCalvo, EmilianoGil-Martin, MartaMartinez-Garcia, MariaBahleda, RastilavCassier, PhilippeDelord, Jean-PierrePrawira, AmyMelero, IgnacioEmens, LeishaRomano, EmanuelaMiller, KarenHsieh, Robert W.Xue, ClorisMorrissey, KariTwomey, PatrickGash, KellyPatil, Namrata S.Grogan, JaneMeng, RaymondCho, ByoungKim, Tae Won
- [50] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224Infante, Jeffrey R.Mendelson, David S.Burris, Howard A., IIIBendell, Johanna C.Tolcher, Anthony W.Gordon, Michael S.Gillenwater, Heidi H.Arastu-Kapur, ShirinWong, Hansen L.Papadopoulos, Kyriakos P.